methotrexate has been researched along with Chemotherapy-Induced Febrile Neutropenia in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Fanale, M; Fayad, LE; Feng, L; Ford, P; Fowler, N; Goy, A; Hagemeister, F; Hartig, K; Kantarjian, HM; Kwak, LW; McLaughlin, P; Medeiros, LJ; Naig, A; Neelapu, S; Oki, Y; Orlowski, R; Pro, B; Rodriguez, MA; Romaguera, JE; Samaniego, F; Smith, J; Valentinetti, M; Wang, M; Younes, A | 1 |
1 trial(s) available for methotrexate and Chemotherapy-Induced Febrile Neutropenia
| Article | Year |
|---|---|
Phase 2 trial of bortezomib in combination with rituximab plus hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone alternating with bortezomib, rituximab, methotrexate, and cytarabine for untreated mantle cell lymphoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Chemotherapy-Induced Febrile Neutropenia; Cyclophosphamide; Cytarabine; Dexamethasone; Dose-Response Relationship, Drug; Doxorubicin; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Incidence; Kaplan-Meier Estimate; Lymphoma, Mantle-Cell; Male; Methotrexate; Middle Aged; Neoplasm Recurrence, Local; Prospective Studies; Rituximab; Survival Rate; Time Factors; Treatment Failure; Vincristine | 2018 |